Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR EBITDA Margin
EBITDA as a percentage of revenue.
Hyperfine, Inc.NASDAQ: HYPR
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -211.8%
EBITDA Margin was -211.8% in Q1 FY2026, up 218.2 pp from a year earlier. On a trailing-twelve-month basis it was -216.2%, up 118.9 pp year over year. Over 3 fiscal years it widened by 812.8 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -136.1% for the fiscal year ending Dec 2026, up from -246.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -211.8%-113.3 pp QoQ
- Last fiscal yearDec 2025
- -246.1%+62.0 pp YoY
- LTMMar 2026
- -216.2%+118.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -246.1%
- Year-over-year change
- +62.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -246.1% | +62.0pp |
| FY2024 | 2024-12-31 | -308.1% | +83.4pp |
| FY2023 | 2023-12-31 | -391.4% | +667.4pp |
| FY2022 | 2022-12-31 | -1058.8% | +3227.6pp |
| FY2021 | 2021-12-31 | -4286.4% | — |
EBITDA Margin vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 EBITDA Margin of -216.2% is the 4th highest of the 6 companies compared; the peer median is -54.5%.
- Its year-over-year change of +118.9 pp is the highest of 6, against a peer median of -3.2 pp.
- Over three fiscal years its change of +812.8 pp compares with a peer median of +4.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.1% | -3.2 pp | -10.6 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -54.5% | +6.4 pp | +50.0 pp | |
| LTM Mar 2026 | -216.2% | +118.9 pp | +812.8 pp | |
IMAImageneBio Inc | FY2025 | -5583.3% | -4582.4 pp | -5147.8 pp |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding HYPR) | -54.5% | -3.2 pp | +4.9 pp | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.5M | 6.81M | 11.03M | 12.89M | 13.56M |
| Cost of Revenue | 2.66M | 5.91M | 6.28M | 7M | 6.81M |
| Gross Profit | (1.17M) | 907K | 4.76M | 5.89M | 6.75M |
| Gross Margin | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Research & Development | 25.84M | 28.16M | 22.49M | 22.5M | 17.45M |
| Selling, General & Admin | 37.86M | 46.63M | 30.38M | 26.62M | 26.39M |
| Operating Expenses | 63.7M | 74.78M | 52.87M | 49.12M | 43.84M |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 2.2M |
| EBITDA | (64.13M) | (72.15M) | (43.18M) | (39.71M) | (33.37M) |
| EBITDA Margin | -4286.4% | -1058.8% | -391.4% | -308.1% | -246.1% |
| Operating Income | (64.87M) | (73.87M) | (48.12M) | (43.22M) | (37.09M) |
| Operating Margin | -4336.1% | -1084.2% | -436.1% | -335.3% | -273.4% |
| Interest Income | 18K | 761K | 3.84M | 2.49M | 1.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17K | 710K | 3.88M | 2.5M | 1.51M |
| Income Before Tax | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Pre-Tax Margin | -4335.0% | -1073.7% | -401.0% | -315.9% | -262.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (64.83M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Net Margin | -4333.8% | -1073.7% | -401.0% | -315.9% | -262.3% |
| EPS (Basic) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| EPS (Diluted) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| Weighted Avg Shares | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
| Weighted Avg Shares (Diluted) | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.